An Oleanolic Acid Derivative Inhibits Hemagglutinin-Mediated Entry of Influenza A Virus

[tetano]

Viruses. 2020 Feb 18;12(2). pii: E225. doi: 10.3390/v12020225. An Oleanolic Acid Derivative Inhibits Hemagglutinin-Mediated Entry of Influenza A Virus.

Ye M^1,2, Liao Y³, Wu L², Qi W², Choudhry N^1,2, Liu Y^1,2, Chen W⁴, Song G³, Chen J^1,2.
Author information

Abstract

Influenza A viruses (IAV) have been a major public health threat worldwide, and options for antiviral therapy become increasingly limited with the emergence of drug-resisting virus strains. New and effective anti-IAV drugs, especially for highly pathogenic influenza, with different modes of action, are urgently needed. The influenza virus glycoprotein hemagglutinin (HA) plays critical roles in the early stage of virus infection, including receptor binding and membrane fusion, making it a potential target for the development of anti-influenza drugs. In this study, we show that OA-10, a newly synthesized triterpene out of 11 oleanane-type derivatives, exhibited significant antiviral activity against four different subtypes of IAV (H1N1, H5N1, H9N2 and H3N2) replications in A549 cell cultures with EC₅₀ ranging from 6.7 to 19.6 μM and a negligible cytotoxicity (CC₅₀ > 640 μM). It inhibited acid-induced hemolysis in a dose-dependent manner, with an IC₅₀ of 26 ?M, and had a weak inhibition on the adsorption of H5 HA to chicken erythrocytes at higher concentrations (≥40 ?M). Surface plasmon resonance (SPR) analysis showed that OA-10 interacted with HA in a dose-dependent manner with the equilibrium dissociation constants (KD) of the interaction of 2.98 ? 10^-12 M. Computer-aided molecular docking analysis suggested that OA-10 might bind to the cavity in HA stem region which is known to undergo significant rearrangement during membrane fusion. Our results demonstrate that OA-10 inhibits H5N1 IAV replication mainly by blocking the conformational changes of HA2 subunit required for virus fusion with endosomal membrane. These findings suggest that OA-10 could serve as a lead for further development of novel virus entry inhibitors to prevent and treat IAV infections.


KEYWORDS:

hemagglutinin (HA); influenza A virus (IAV); oleanane-type derivatives; virus entry inhibitors

PMID: 32085430 DOI: 10.3390/v12020225